巴瑞替尼或拉武利珠单抗治疗成人重症COVID-19的疗效与安全性:TACTIC-R随机平行组开放标签4期试验
TACTIC-R是一项在英国22家医院进行的4期随机平行组开放标签平台试验,纳入417例重症COVID-19成人患者,随机分为标准治疗组、标准治疗+巴瑞替尼组和标准治疗+拉武利珠单抗组。主要复合终点为随机化至14天内首次发生死亡、有创机械通气、ECMO、心血管器官支持或肾衰竭的时间。因无效提前终止,巴瑞替尼和拉武利珠单抗均未显著降低疾病严重程度,安全性相似。
要点
- 巴瑞替尼和拉武利珠单抗均未改善重症COVID-19患者的复合主要终点。
- 巴瑞替尼组仅39%患者完成最大14天疗程,可能影响结果解读。
- 两组严重不良事件数与标准治疗组相似,安全性无显著差异。
核心结论
- 巴瑞替尼和拉武利珠单抗按本研究方案给药均未能降低重症COVID-19患者的疾病严重程度。
- 两种治疗的安全性均与标准治疗相似。
研究设计与样本
- TACTIC-R是一项在英国22家医院开展的4期随机、平行组、开放标签平台试验。
- 共纳入417例成人(≥18岁)重症COVID-19住院患者,随机1:1:1分配至标准治疗组(145例)、巴瑞替尼组(137例)或拉武利珠单抗组(135例)。
- 主要复合终点为随机化至14天内首次发生死亡、有创机械通气、ECMO、心血管器官支持或肾衰竭的时间。
主要发现
- 标准治疗组报告45例严重不良事件(21例死亡),巴瑞替尼组57例(24例死亡),拉武利珠单抗组60例(18例死亡)。
- 巴瑞替尼组137例中仅54例(39%)接受最大14天疗程,拉武利珠单抗组135例中132例(98%)接受预期剂量。
- 试验在主要中期分析后因无效而终止。
临床怎么用
- 不推荐将巴瑞替尼或拉武利珠单抗按本研究方案用于重症COVID-19的常规治疗。
- 巴瑞替尼疗程不足可能解释与其他试验的差异,临床应用时需确保足够疗程。
- 靶向补体C5a而非C5裂解的潜在治疗价值有待进一步评估。
局限性
- 开放标签设计可能引入偏倚。
- 巴瑞替尼组仅39%患者完成最大14天疗程,给药时间短可能影响疗效评估。
- 试验因无效提前终止,样本量可能不足以检测较小差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: From early in the COVID-19 pandemic, evidence suggested a role for cytokine dysregulation and complement activation in severe disease. In the TACTIC-R trial, we evaluated the efficacy and safety of baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, and ravulizumab, a monoclonal inhibitor of complement C5 activation, as an adjunct to standard of care for the treatment of adult patients hospitalised with COVID-19. METHODS: TACTIC-R was a phase 4, randomised, parallel-arm, open-label platform trial that was undertaken in the UK with urgent public health designation to assess the potential of repurposing immunosuppressants for the treatment of severe COVID-19, stratified by a risk score. Adult participants (aged ≥18 years) were enrolled from 22 hospitals across the UK. Patients with a risk score indicating a 40% risk of admission to an intensive care unit or death were randomly assigned 1:1:1 to standard of care alone, standard of care with baricitinib, or standard of care with ravulizumab. The composite primary outcome was the time from randomisation to incidence (up to and including day 14) of the first event of death, invasive mechanical ventilation, extracorporeal membrane oxygenation, cardiovascular organ support, or renal failure. The primary interim analysis was triggered when 125 patient datasets were available up to day 14 in each study group and we included in the analysis all participants who were randomly assigned. The trial was registered on ClinicalTrials.gov (NCT04390464). FINDINGS: Between May 8, 2020, and May 7, 2021, 417 participants were recruited and randomly assigned to standard of care alone (145 patients), baricitinib (137 patients), or ravulizumab (135 patients). Only 54 (39%) of 137 patients in the baricitinib group received the maximum 14-day course, whereas 132 (98%) of 135 patients in the ravulizumab group received the intended dose. The trial was stopped after the primary interim analysis on grounds of futility. The estimated hazard ratio (HR) for reaching the composite primary endpoint was 1·11 (95% CI 0·62-1·99) for patients on baricitinib compared with standard of care alone, and 1·53 (0·88-2·67) for ravulizumab compared with standard of care alone. 45 serious adverse events (21 deaths) were reported in the standard-of-care group, 57 (24 deaths) in the baricitinib group, and 60 (18 deaths) in the ravulizumab group. INTERPRETATION: Neither baricitinib nor ravulizumab, as administered in this study, was effective in reducing disease severity in patients selected for severe COVID-19. Safety was similar between treatments and standard of care. The short period of dosing with baricitinib might explain the discrepancy between our findings and those of other trials. The therapeutic potential of targeting complement C5 activation product C5a, rather than the cleavage of C5, warrants further evaluation. FUNDING: UK Medical Research Council, UK National Institute for Health Research Cambridge Biomedical Research Centre, Eli Lilly and Company, Alexion Pharmaceuticals, and Addenbrooke's Charitable Trust.
引用
- Hall FC, Cheriyan J, Cope AP, et al. Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial. Lancet Respir Med. 2023. PMID: 37977159. doi:10.1016/S2213-2600(23)00376-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。